home / stock / thor / thor news

THOR News and Press, Synthorx Inc. From 09/23/19

Stock Information
Company Name: Synthorx Inc.
Stock Symbol: THOR
Market: NASDAQ
Website: synthorx.com
Menu
THOR THOR Quote THOR Short THOR News THOR Articles THOR Message Board
Get THOR Alerts

News, Short Squeeze, Breakout and More Instantly...
THOR - Synthorx to Present at the European Society for Medical Oncology (ESMO) 2019 Congress

SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced that preclinical data for immuno-oncology product candidate, THOR-707, will be presented...
THOR - Synthorx to Present at the 2019 World Congress of Inflammation

SAN DIEGO, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced the details of a scientific presentation characterizing THOR-809, a Synthorin™ fo...

THOR - Synthorx to Present at H.C. Wainwright 21st Annual Global Investment Conference

SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced the Company will present at the H.C. Wainwright 21 st Annual Global Investment Conferenc...

THOR - Synthorx EPS misses by $0.01

Synthorx (NASDAQ: THOR ): Q2 GAAP EPS of -$0.39 misses by $0.01 . More news on: Synthorx, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

THOR - Synthorx Reports Second Quarter Financial Results

SAN DIEGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (Nasdaq: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today reported financial results and provided a business update for the second quarter ended June 30, 201...

THOR - Synthorx Initiates Patient Dosing in Australia and Announces Clearance of IND in the U.S. for Lead Immuno-oncology Product Candidate, THOR-707

SAN DIEGO, July 24, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, announced today it has opened HAMMER, a global, Phase 1/2, first-in-human clinical trial of THOR-707, wit...

THOR - Clinical Data Making A Stronger Case For Nektar Therapeutics

I’ve been what I’d call “cautiously bullish” on Nektar ( NKTR ) and its lead drug bempegaldesleukin (formerly known as NKTR-214, I’m going with “bempeg” for short); while the idea of a safer form of IL-2 to accompany PD-1 antibodies and other ...
THOR - Synthorx to Present at Jefferies 2019 Healthcare Conference

SAN DIEGO, May 29, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced the Company will presen...

THOR - Synthorx to Present at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

SAN DIEGO, May 15, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a biotechnology company discovering and developing optimized biologics for cancer and autoimmune disorders, today announced company researchers will present preclinical data demonstrating the potential safety and ant...

THOR - Synthorx misses by $0.07

Synthorx (NASDAQ: THOR ): Q1 GAAP EPS of -$0.35  misses by $0.07 . More news on: Synthorx, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Previous 10 Next 10